Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35977178.
- Also identified by DOI 10.1001/jamahealthforum.2021.2634 and PMC identifier 8796923.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.
Medical subject headings
- Biosimilar Pharmaceuticals
- Medicare Part B